What is Unicycive Therapeutics, Inc.'s earnings per share (EPS)?

Unicycive Therapeutics, Inc. (UNCY) reported diluted earnings per share of -$1.67 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Unicycive Therapeutics, Inc. (UNCY) Financials

UNCY

FY2025 annual

Net Income -$26.6M +27.7% YoY

EPS (Diluted) -$1.67 YoY not available

Free Cash Flow -$31.3M -9.4% YoY

Operating Cash Flow -$31.3M -9.6% YoY

Market Cap $113.4M as of Oct 9, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.1x on $53.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UNCY SEC filings page.

This page shows Unicycive Therapeutics, Inc. (UNCY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UNCY FY2025 2026-10-04

This development-stage business is funded mainly by financing while operations continue consuming cash and reported revenue remains limited.

Across FY2024 and FY2025, operating cash outflow stayed near $30M while financing inflows exceeded $45M in each year, so balance-sheet improvement came primarily from capital raised rather than internal cash generation. The near match between FY2025 operating cash outflow of $31.3M and net loss of $26.6M, alongside only $24K of capital spending, indicates that cash consumption is driven mainly by ongoing operating expenses rather than heavy physical reinvestment.

Spending mix shifted materially: R&D fell from $20.0M in FY2024 to $9.1M in FY2025. SG&A rose to $20.4M while operating loss remained $29.5M, indicating that lower research spending did not yet reduce total operating losses.

The short-term balance sheet strengthened: current ratio improved from 1.3x in FY2024 to 2.6x in FY2025, while liabilities fell. Equity rose to $30.2M and reported liquidity equaled 15.8 months of the latest annual operating outflow; paired with recurring negative operating cash flow, that improvement reflects financing capacity rather than self-funding operations.

Financial Health Signals

Financial health score not available

Unicycive Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Unicycive Therapeutics, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Unicycive Therapeutics, Inc. reported a net loss of $26.6M while operations used $31.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Unicycive Therapeutics, Inc. reported an operating loss of $29.5M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.1M

YoY-45.7%

QoQ-20.2%

Unicycive Therapeutics, Inc.'s EBITDA was -$10.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 45.7% from the same quarter a year earlier. Against the prior quarter it is down 20.2%.

Net Income

-$1.7M

YoY+73.3%

QoQ+86.6%

Unicycive Therapeutics, Inc. reported -$1.7M in net income in Q2 2026. This represents an increase of 73.3% from the same quarter a year earlier. Against the prior quarter it is up 86.6%.

EPS (Diluted)

-$0.06

QoQ+88.9%

Unicycive Therapeutics, Inc. earned -$0.06 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 88.9%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$7.6M

YoY+9.7%

QoQ-21.7%

Unicycive Therapeutics, Inc. recorded an outflow of $7.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 9.7% from the same quarter a year earlier. Against the prior quarter it is down 21.7%.

Cash & Debt

$44.2M

YoY+97.9%

QoQ+18.2%

5Y CAGR+749.3%

Unicycive Therapeutics, Inc. held $44.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

28M

QoQ+4.3%

5Y CAGR+13.9%

Unicycive Therapeutics, Inc. had 28M shares outstanding in Q2 2026. Against the prior quarter it is up 4.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-3.2%

YoY+36.0pp

QoQ+30.8pp

Unicycive Therapeutics, Inc.'s ROE was -3.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 36.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 30.8 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.8M

YoY+59.3%

QoQ+73.5%

Unicycive Therapeutics, Inc. invested $2.8M in research and development in Q2 2026. This represents an increase of 59.3% from the same quarter a year earlier. Against the prior quarter it is up 73.5%.

Capital Expenditures

$1K

YoY-83.3%

QoQ-87.5%

Unicycive Therapeutics, Inc. invested $1K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 83.3% from the same quarter a year earlier. Against the prior quarter it is down 87.5%.

Share Buybacks

Not reported for Q2 2026.

UNCY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UNCY quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	N/A	$675K-29.0%	$951K	N/A	N/A
R&D Expenses	N/A	$9.1M-54.4%	$20.0M+55.1%	$12.9M+3.7%	$12.4M+104.5%	$6.1M+499.0%	$1.0M
SG&A Expenses	N/A	$20.4M+68.5%	$12.1M+41.6%	$8.5M+2131.6%	$383K+56.3%	$245K+322.4%	$58K
Operating Income	N/A	-$29.5M+8.1%	-$32.1M-54.6%	-$20.8M	N/A	-$9.0M	N/A
EBITDA	N/A	-$29.5M+8.1%	-$32.1M-54.6%	-$20.8M	N/A	-$8.5M	N/A
Interest Expense	N/A	$71K0.0%	$71K-13.4%	$82K+1266.7%	$6K-99.0%	$628K+157.4%	$244K
Net Income	N/A	-$26.6M+27.7%	-$36.7M-20.2%	-$30.5M	N/A	-$10.0M	N/A
EPS (Basic)	N/A	-$1.67+70.4%	-$5.65-341.4%	-$1.28-6.7%	-$1.20-39.5%	-$0.86-218.5%	-$0.27
EPS (Diluted)	-$1.75	-$1.67	-$5.65	-$1.28	-$1.20-39.5%	-$0.86	N/A
Diluted Shares (Avg)	N/A	16M	7M	25M	15M+29.0%	12M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$2.8M+59.3%	$1.6M-26.0%	N/A	$3.0M-2.7%	$1.8M-64.1%	$2.2M-68.1%	N/A	$3.0M-9.7%
SG&A Expenses	$7.4M+41.0%	$6.8M+17.4%	N/A	$4.4M+36.6%	$5.2M+105.8%	$5.8M+143.3%	N/A	$3.2M+569.3%
Operating Income	-$10.1M-45.6%	-$8.4M-5.6%	N/A	-$7.3M-17.5%	-$7.0M+5.9%	-$8.0M+13.2%	N/A	-$6.3M-5.3%
EBITDA	-$10.1M-45.7%	-$8.4M-5.6%	N/A	-$7.3M-17.4%	-$7.0M+6.0%	-$8.0M+13.2%	N/A	-$6.2M-5.2%
Interest Expense	N/A	N/A	N/A	$15K0.0%	$13K-18.8%	$15K-25.0%	N/A	$15K-16.7%
Net Income	-$1.7M+73.3%	-$12.8M-2349.6%	N/A	-$6.0M-46.8%	-$6.4M-165.4%	$570K+102.7%	N/A	-$4.1M+5.5%
EPS (Basic)	-$0.06+88.5%	-$0.54-1450.0%	-$0.82-215.4%	-$0.33+28.3%	-$0.52-165.0%	$0.04+106.6%	-$0.26-62.5%	-$0.46-253.8%
EPS (Diluted)	-$0.06	-$0.54	-$0.82	-$0.33	-$0.52	-$0.50	-$0.26	-$0.46
Diluted Shares (Avg)	27M	24M	N/A	18M	12M	12M	N/A	9M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

UNCY Balance Sheet

UNCY quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$49.1M+55.2%	$31.7M+123.2%	$14.2M+403.6%	$2.8M-85.0%	$18.7M+9088.2%	$204K
Current Assets	$49.0M+58.2%	$30.9M+131.0%	$13.4M+406.8%	$2.6M-85.6%	$18.4M+8925.0%	$204K
Cash & Equivalents	$29.2M+11.7%	$26.1M+169.5%	$9.7M+2032.1%	$455K-97.3%	$16.6M	N/A
Short-Term Investments	$12.1M	$0	$0	$0	$0	N/A
Inventory	N/A	N/A	N/A	$2.2M+19.5%	$1.8M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	N/A
Total Liabilities	$18.9M-21.9%	$24.2M+34.6%	$18.0M+448.1%	$3.3M+45.3%	$2.3M-21.4%	$2.9M
Current Liabilities	$18.9M-21.5%	$24.1M+37.6%	$17.5M+433.9%	$3.3M+56.0%	$2.1M-26.8%	$2.9M
Non-Current Liabilities	$0-100.0%	$117K-74.9%	$466K	$0-100.0%	$155K	$0
Total Equity	$30.2M+306.4%	$7.4M+295.1%	-$3.8M-717.4%	-$466K-102.8%	$16.5M+717.1%	-$2.7M
Retained Earnings	-$127.8M-26.2%	-$101.3M-56.9%	-$64.5M-89.8%	-$34.0M-113.3%	-$15.9M-169.1%	-$5.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$72.0M+140.1%	$64.4M+130.5%	$49.1M+55.2%	$50.6M+31.2%	$30.0M-32.9%	$27.9M-46.7%	$31.7M+123.2%	$38.6M+98.4%
Current Assets	$71.3M+141.5%	$63.5M+132.4%	$49.0M+58.2%	$50.3M+33.2%	$29.5M-33.0%	$27.3M-47.1%	$30.9M+131.0%	$37.7M+103.2%
Cash & Equivalents	$44.2M+97.9%	$37.4M+89.0%	$29.2M+11.7%	$42.7M+32.0%	$22.3M-46.6%	$19.8M-59.6%	$26.1M+169.5%	$32.3M+125.5%
Short-Term Investments	$17.2M	$17.2M	$12.1M	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$18.8M+38.3%	$26.7M+60.1%	$18.9M-21.9%	$13.1M-80.2%	$13.6M-77.2%	$16.7M-78.3%	$24.2M+34.6%	$66.4M+314.9%
Current Liabilities	$18.7M+37.9%	$26.5M+58.8%	$18.9M-21.5%	$13.1M+25.5%	$13.6M+3.7%	$16.7M-44.9%	$24.1M+37.6%	$10.5M-32.3%
Non-Current Liabilities	$55K	$217K	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$117K-74.9%	$56.0M+10038.6%
Total Equity	$53.3M+224.2%	$37.7M+234.5%	$30.2M+306.4%	$37.5M+234.6%	$16.4M+210.7%	$11.3M+146.1%	$7.4M+295.1%	-$27.9M-911.0%
Retained Earnings	-$142.4M-32.9%	-$140.6M-10.1%	-$127.8M-26.2%	-$113.2M-41.9%	-$107.1M-41.6%	-$127.8M-49.5%	-$101.3M-56.9%	-$79.7M-40.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

UNCY Cash Flow Statement

UNCY quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$27.8M	-$31.3M-9.6%	-$28.6M-56.3%	-$18.3M	N/A	-$5.8M	N/A
Depreciation & Amortization	N/A	$34K+54.5%	$22K+144.4%	$9K-97.9%	$428K-8.5%	$468K+642.9%	$63K
Stock-Based Compensation	N/A	$2.6M+12.4%	$2.4M+33.0%	$1.8M+68.8%	$1.0M+8.4%	$966K+316.4%	$232K
Capital Expenditures	$9K	$24K-66.7%	$72K+500.0%	$12K+500.0%	$2K-93.1%	$29K	N/A
Free Cash Flow	-$27.9M	-$31.3M-9.4%	-$28.6M-56.6%	-$18.3M	N/A	-$5.8M	N/A
Investing Cash Flow	-$17.3M	-$12.1M-16698.6%	-$72K-500.0%	-$12K-500.0%	-$2K+93.1%	-$29K	N/A
Financing Cash Flow	$66.9M	$46.5M+3.1%	$45.1M+63.7%	$27.5M+5947.3%	-$471K-102.1%	$22.4M	N/A
Dividends Paid	N/A	N/A	$1.1M+21.7%	$900K	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.6M+9.7%	-$6.2M+29.9%	-$8.0M-22.7%	-$6.0M+35.6%	-$8.4M-33.2%	-$8.9M-37.9%	-$6.5M-47.5%	-$9.3M-109.2%
Depreciation & Amortization	$6K0.0%	$8K0.0%	$10K+42.9%	$10K+66.7%	$6K	$8K-11.1%	$7K+133.3%	$6K+200.0%
Stock-Based Compensation	$2.9M+404.0%	$754K+33.9%	N/A	$729K+20.5%	$571K-10.9%	$563K+7.9%	N/A	$605K-34.9%
Capital Expenditures	-$1K-83.3%	$8K-50.0%	$0-100.0%	$2K-91.7%	$6K-70.0%	$16K+166.7%	$22K	$24K
Free Cash Flow	-$7.6M+9.7%	-$6.2M+29.9%	-$8.0M-22.3%	-$6.0M+35.7%	-$8.4M-32.9%	-$8.9M-38.0%	-$6.6M-48.0%	-$9.3M-109.8%
Investing Cash Flow	-$23K-283.3%	-$5.2M-32118.8%	-$12.1M-54768.2%	-$2K+91.7%	-$6K+70.0%	-$16K-166.7%	-$22K	-$24K
Financing Cash Flow	$14.4M+31.5%	$19.6M+668.6%	$6.6M+1709.9%	$26.3M+16872.0%	$11.0M+1454.4%	$2.5M-94.4%	$365K+278.0%	-$157K-207.8%
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%

Not reported in any period shown, so not listed: Share Buybacks.

UNCY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UNCY quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Margin	N/A	N/A	-3077.6%	N/A	N/A	N/A
Net Margin	N/A	N/A	-4525.0%	N/A	N/A	N/A
Return on Equity	-87.9%+406.3pp	-494.3%	N/A	N/A	-60.8%	N/A
Return on Assets	-54.0%+61.9pp	-116.0%+99.3pp	-215.2%	N/A	-53.4%	N/A
Current Ratio	2.59+1.3x	1.28+0.5x	0.760.0x	0.81-7.9x	8.75+8.7x	0.07
Debt-to-Equity	0.63-2.6x	3.26	N/A	N/A	0.14	N/A
Asset Turnover	N/A	N/A	0.05-0.3x	0.34	N/A	N/A
FCF Margin	N/A	N/A	-2710.4%	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-3.2%+36.0pp	-34.0%-39.1pp	N/A	-16.0%	-39.2%	5.1%	N/A	N/A
Return on Assets	-2.4%+19.1pp	-19.9%-21.9pp	N/A	-11.9%-1.3pp	-21.5%-43.5pp	2.0%+42.1pp	N/A	-10.6%+11.7pp
Current Ratio	3.81+1.6x	2.40+0.8x	2.59+1.3x	3.83+0.2x	2.18-1.2x	1.64-0.1x	1.28+0.5x	3.61+2.4x
Debt-to-Equity	0.35-0.5x	0.71-0.8x	0.63-2.6x	0.35	0.83	1.48	3.26	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Unicycive Therapeutics, Inc. UNCY	FY2025	N/A	-$26.6M	N/A	$113.4M	—
Vivani Medical, Inc. VANI	FY2025	$0	$26.6M	N/A	$114.6M	—
OS Therapies Incorporated OSTX	FY2025	N/A	-$28.8M	N/A	$72.5M	—
ANEBULO PHARMAC INC ANEB	FY2025	N/A	-$8.5M	N/A	$14.7M	—
Cel-Sci Corporation CVM	FY2025	N/A	-$25.4M	N/A	$37.5M	—

Where Unicycive Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Unicycive Therapeutics, Inc. profitable?

No, Unicycive Therapeutics, Inc. (UNCY) reported a net income of -$26.6M in fiscal year 2025.

What is Unicycive Therapeutics, Inc.'s EBITDA?

Unicycive Therapeutics, Inc. (UNCY) had EBITDA of -$29.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Unicycive Therapeutics, Inc.'s return on equity (ROE)?

Unicycive Therapeutics, Inc. (UNCY) has a return on equity of -87.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Unicycive Therapeutics, Inc.'s free cash flow?

Unicycive Therapeutics, Inc. (UNCY) recorded an outflow of $31.3M in free cash flow during fiscal year 2025. This represents a -9.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Unicycive Therapeutics, Inc.'s operating cash flow?

Unicycive Therapeutics, Inc. (UNCY) recorded an outflow of $31.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Unicycive Therapeutics, Inc.'s total assets?

Unicycive Therapeutics, Inc. (UNCY) had $49.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Unicycive Therapeutics, Inc.'s capital expenditures?

Unicycive Therapeutics, Inc. (UNCY) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Unicycive Therapeutics, Inc. spend on research and development?

Unicycive Therapeutics, Inc. (UNCY) invested $9.1M in research and development during fiscal year 2025.

How many shares does Unicycive Therapeutics, Inc. have outstanding?

Unicycive Therapeutics, Inc. (UNCY) had 25M shares outstanding as of fiscal year 2025.

What is Unicycive Therapeutics, Inc.'s current ratio?

Unicycive Therapeutics, Inc. (UNCY) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.

What is Unicycive Therapeutics, Inc.'s debt-to-equity ratio?

Unicycive Therapeutics, Inc. (UNCY) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Unicycive Therapeutics, Inc.'s return on assets (ROA)?

Unicycive Therapeutics, Inc. (UNCY) had a return on assets of -54.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Unicycive Therapeutics, Inc.'s P/E ratio?

Unicycive Therapeutics, Inc. (UNCY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $113.4M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Unicycive Therapeutics, Inc.'s price-to-sales ratio?

Unicycive Therapeutics, Inc. (UNCY) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $113.4M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Unicycive Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Unicycive Therapeutics, Inc. (UNCY) held $41.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $31.3M over that year. Dividing the one by the other, the reported balance equals about 16 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Unicycive Therapeutics, Inc.'s Piotroski F-Score?

Unicycive Therapeutics, Inc. (UNCY) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Unicycive Therapeutics, Inc.'s earnings high quality?

Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $26.6M while operations used $31.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Unicycive Therapeutics, Inc. cover its interest payments?

Unicycive Therapeutics, Inc. (UNCY) reported an operating loss of $29.5M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.